TY - JOUR
T1 - Progress and challenges in the therapy of adult acute lymphoblastic leukemia
AU - Kebriaei, Partow
AU - Larson, Richard A.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2003/7
Y1 - 2003/7
N2 - Acute lymphoblastic leukemia is a heterogeneous disease with distinct biologic and prognostic groupings. Although current therapies result in high complete remission rates, long-term disease-free survival rates have remained disappointingly low. Results from recent studies using risk-tailored approaches suggest improvement in overall survival for high-risk groups, such as those with Philadelphia chromosome-positive acute lymphoblastic leukemia. Furthermore, the incorporation of imatinib mesylate into the treatment regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia patients may lead to better outcomes. Finally, quantification of minimal residual disease at various time points during therapy is being investigated as a means to predict more accurately a patient's response to therapy, and to make therapeutic decisions.
AB - Acute lymphoblastic leukemia is a heterogeneous disease with distinct biologic and prognostic groupings. Although current therapies result in high complete remission rates, long-term disease-free survival rates have remained disappointingly low. Results from recent studies using risk-tailored approaches suggest improvement in overall survival for high-risk groups, such as those with Philadelphia chromosome-positive acute lymphoblastic leukemia. Furthermore, the incorporation of imatinib mesylate into the treatment regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia patients may lead to better outcomes. Finally, quantification of minimal residual disease at various time points during therapy is being investigated as a means to predict more accurately a patient's response to therapy, and to make therapeutic decisions.
UR - http://www.scopus.com/inward/record.url?scp=0037632760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037632760&partnerID=8YFLogxK
U2 - 10.1097/00062752-200307000-00006
DO - 10.1097/00062752-200307000-00006
M3 - Review article
C2 - 12799534
AN - SCOPUS:0037632760
SN - 1065-6251
VL - 10
SP - 284
EP - 289
JO - Current opinion in hematology
JF - Current opinion in hematology
IS - 4
ER -